DOCSLIB.ORG

Mark B. Mcclellan, M.D., Ph.D. Duke University 100 Fuqua Drive Box 90120 Durham N.C

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mark B. Mcclellan, M.D., Ph.D. Duke University 100 Fuqua Drive Box 90120 Durham N.C CURRICULUM VITAE MARK B. MCCLELLAN, M.D., PH.D. DUKE UNIVERSITY 100 FUQUA DRIVE BOX 90120 DURHAM N.C. 27708 EDUCATION: 1993 Ph.D., Economics, Massachusetts Institute of Technology 1992 M.D., Harvard-MIT Division of Health Science and Technology, cum laude 1991 M.P.A., Regulatory Policy, Kennedy School of Government, Harvard University 1985 B.A., English/Biology, University of Texas, Austin, summa cum laude CLINICAL TRAINING: 1996 Diplomate, American Board of Internal Medicine 1993 – 1995 Resident in Internal Medicine, Department of Medicine, Brigham and Women's Hospital EMPLOYMENT: CURRENT POSTION 2015 - Present Director of the Duke-Margolis Center for Health Policy 2015 - Present Robert J. Margolis MD Professor of Business, Medicine and Health Policy 2015 - Present Faculty Member & Sr. Policy Advisor, University of Texas, Austin, Dell Medical School PREVIOUS POSITIONS 2007 – 2015 Senior Fellow in Economic Studies, Brookings Institution 2013 – 2015 Director, Initiatives on Value and Innovation in Health Care, Brookings Institution 2007 – 2013 Director, Engelberg Center for Health Care Reform, Brookings Institution 2006 – 2007 Visiting Senior Fellow, AEI-Brookings Joint Center for Regulatory Studies, American Enterprise Institute and the Brookings Institution 2004 – 2006 Administrator, Centers for Medicare and Medicaid Services, U.S. Department of Health and Human Services 2002 – 2004 Commissioner, U. S. Food and Drug Administration 2001 – 2002 Member, Council of Economic Advisers, and Senior Director for Health Care Policy, White House 2000 – 2007 Associate Professor with tenure, Department of Economics and Department of Medicine, Stanford University (on leave 2001-2007) 1998 – 1999 Deputy Assistant Secretary for Economic Policy, U.S. Department of the Treasury 1998 – 2001 Director, Program on Health Outcomes Research, Stanford Medical School 1995 – 1999 Assistant Professor, Department of Economics and Department of Medicine, Stanford University 1995 – 2001 Attending Physician in Internal Medicine, Stanford Health Services 1991 – 1995 Research Associate, Department of Health Care Policy, Harvard Medical School 1989 – 1991 Consultant, RAND Corporation 1 ADVISORY POSITIONS AND AFFILIATIONS: Board Member, Alignment Healthcare Board Member, Cigna Corporation Board Member, FasterCures Board Member, Institute for Accountable Care Board Member, Johnson & Johnson Board Member, Long-Term Quality Alliance Board Member, National Alliance for Hispanic Health Board Member, PrognomIQ Board Member, Research!America Board Member, West Health Institute Sr. Advisor, Reagan-Udall Foundation Advisory Board Member, Arsenal Healthcare Advisory Board Member, Peterson Center on Healthcare Advisory Board Member, USofCare Advisor, American Well Advisor, Blackstone Life Sciences Advisor, Center for Aging Services Technologies Advisor, CRG Advisor, HealthMine Advisor, Health Tech 4 Medicaid Advisor, MITRE Research Associate, National Bureau of Economic Research (Aging and Health Care Programs) Represented Speaker, Washington Speakers Bureau Executive Committee Chair, Clinical Trials Transformation Initiative Co-Chair, Health Care Payment Learning & Action Network (HCP-LAN) Chair, National Academy of Medicine Consortium for a Value and Science-Driven Health System Member, National Academy of Medicine, National Academy of Sciences Member, National Academy of Social Insurance SELECTED HONORS AND AWARDS: 1985 Phi Beta Kappa 1988 John F. Kennedy Fellowship in Public Policy (Harvard University) 1992 Aesculapian Society (Harvard Medical School) 1994 Review of Economic Studies Award, Outstanding Dissertation in Economics 1994 Finalist, National Academy of Social Insurance Dissertation Prize 1995 Finalist, Best Research Paper, Association for Health Services Research 1996 John M. Olin Faculty Research Fellowship 1997 Kenneth Arrow Award, Best Research Paper in Health Economics 1999 Career Development Award, National Institute on Aging 1999 Griliches Award, Best Empirical Research Paper, Quarterly Journal of Economics/Journal of. Political Economy 2000 National Fellow, Hoover Institution 2001 Kenneth Arrow Award, Best Research Paper in Health Economics 2003 Elected to Institute of Medicine, National Academy of Sciences 2003 VIDA (Vision, Innovation, Dedication, and Advocacy) Award, National Alliance for Hispanic Health 2003 Indispensable Person in Health Research Award, Alliance for Aging Research 2004 Cancer Leadership Award, Friends of Cancer Research 2 2004 King David Award for Public Leadership, Jerusalem Fund 2005 AMA Joseph F. Boyle Award for Distinguished Public Service 2005 Public Service Leadership Award, National Coalition for Cancer Survivorship 2006 Booker T. Washington Award, National Minority Health Month Foundation 2006 The Surgeon General’s Medallion for Outstanding Commitment and Dedication to the Health and Welfare of All People, and Exemplary Service in the Public Trust 2008 The Presidential Citation in Recognition of Contributions to Promoting High Quality Innovative and Affordable Health Care, The American College of Cardiology 2008 The American College of Cardiology Foundation 39th Annual Louis F. Bishop Lecturer, 57th Annual Scientific Session 2008 Star of Texas Healthcare Award 2009 Marshall Seidman Distinguished Lecturer in Health Policy, Harvard Medical School 2011 Cutter Lecture on Preventive Medicine, Harvard School of Public Health 2013 Thomas Ferguson Distinguished Lecturer, American Society of Thoracic Surgeons 2014 Pollock Distinguished Lecture, American Society of Neuroradiology Fogarty Distinguished Lecturer, Stanford University 2015 Visiting Fellow, Hoover Institution 2016 Harvey Wiley Award and Lecture, Distinguished Service for Public Health, Food and Drug Administration Alumni Association and Food and Drug Law Institute 2017 National Association of Health Data Organizations Elliott Stone Award of Excellence in Health Data Leadership PUBLICATIONS: 1. “Appropriateness of Care: A Comparison of Global and Outcome Methods to Set Standards,” Mark B. McClellan, Robert H. Brook. Medical Care. Philadelphia: July, 1992. Vol. 30, Iss. 7; p. 565-586. 2. “Does More Intensive Treatment of Acute Myocardial Infarction in the Elderly Reduce Mortality? Analysis Using Instrumental Variables,” Mark B. McClellan, Barbara J. McNeil, Joseph P. Newhouse. Journal of the American Medical Association. Chicago: September, 1994. Vol. 272, Iss. 11; p. 859-866. 3. “Uncertainty, Health Care Technologies, and Health Care Choices,” Mark B. McClellan. American Economic Review Papers and Proceedings. Nashville: May, 1995. Vol. 85, Iss. 2; p. 38-44. 4. “The Uncertain Demand for Medical Care: A Comment on Emmett Keeler,” Mark B. McClellan. Journal of Health Economics. Amsterdam: June, 1995. Vol. 14, Iss. 2; p. 239-242. 5. “Do Doctors Practice Defensive Medicine?” Daniel P. Kessler, Mark B. McClellan. Quarterly Journal of Economics. Cambridge: May, 1996. Vol. 111, Iss. 2; p. 353-390. 6. “Are the Returns to Technological Change in Health Care Declining?” Mark McClellan. Proceedings of the National Academy of Sciences of the United States of America. Washington: November, 1996. Vol. 93, Iss. 23; p. 12701-12708. 7. “The Marginal Cost-Effectiveness of Medical Technology: A Panel Instrumental-variables Approach,” Mark B. McClellan, Joseph P. Newhouse. Journal of Econometrics. Amsterdam: March, 1997. Vol. 77, Iss. 1; p. 39-64. 8. “Hospital Reimbursement Incentives: An Empirical Analysis,” Mark B. McClellan. Journal of Economics and Management Strategy. Oxford: Spring, 1997. Vol. 6, Iss. 1; p. 91-128. 3 9. “The Effects of Malpractice Pressure and Liability Reforms on Physicians' Perceptions of Medical Care,” Daniel P. Kessler, Mark B. McClellan. Journal of Law and Contemporary Problems. Durham: Winter, 1997. Vol. 60, Iss. 1-2; p. 81-106. 10. “Econometrics in Outcomes Research: The Use of Instrumental Variables,” Joseph P. Newhouse, Mark B. McClellan. Annual Review of Public Health. Palo Alto: May, 1998. Vol. 19; p. 17-34. 11. “Technological Change in Heart-Disease Treatment: Does High-Tech Mean Low Value?” Mark B. McClellan, Haruko Noguchi. American Economic Review. Nashville: May, 1998. Vol. 88, Iss. 2; p. 90-96. 12. “What Has Increased Medical-Care Spending Bought?” David M. Cutler, Mark B. McClellan, Joseph P. Newhouse. American Economic Review. Nashville: May, 1998. Vol. 88, Iss. 2; p. 132- 136. 13. “Are Medical Prices Declining? Evidence from Heart Attack Treatments,” David M. Cutler, Mark B. McClellan, Joseph P. Newhouse, Dahlia Remler. Quarterly Journal of Economics. Cambridge: November, 1998. Vol. 113, Iss. 4; p. 991-1024. 14. “Risks and Costs of End-Stage Renal Disease After Heart Transplantation,” John Hornberger, Jennie Best, Jeffrey Geppert, Mark B. McClellan. Transplantation. Baltimore: December, 1998. Vol. 66, Iss. 12; p. 1763-1770. 15. “Medicare Reform: Who Pays, and Who Benefits?” Mark B. McClellan, Jonathan S. Skinner. Health Affairs. Bethesda: Jan/Feb, 1999. Vol. 18, Iss. 1; p. 48-62. 16. “A Global Analysis of Technological Change in Health Care: The Case of Heart Attacks: Preliminary report from the TECH research network,” Mark B. McClellan, Daniel P. Kessler on behalf of the TECH Investigators. Health Affairs. Bethesda: May, 1999. Vol. 18, Iss. 3: p. 250- 255 17. “How does managed care do it? Prices and productivity in managed care,” David M. Cutler, Mark B. McClellan, Joseph P. Newhouse. RAND Journal of Economics. Santa Monica: Autumn, 2000. Vol. 31, Iss. 3; p. 526-548. 18. “Designing a Medicare Prescription Drug Benefit: Issues, Obstacles and
Load more

Recommended publications
  • Compendium of the Findings of the OPCAST Pandemic Subgroup 12
    1 A Compendium of the Findings of the Obama PCAST Ad Hoc Subgroup on Pandemic Preparedness and Response December 23, 2020 Introduction A subset of the former members of President Obama’s Council of Advisors on Science and Technology (here OPCAST)—ten individuals who played particularly important roles in producing the six OPCAST reports between 2009 and 2016 that dealt with issues related to pandemic preparedness and response1—came together starting in March of this year to consider how insights from those studies might be combined with more recent research and current observations to develop suggestions about how the U.S. response to the COVID-19 pandemic could be improved. The Subgroup has produced six reports, addressing • the national strategic pandemic-response stockpile (May 20) • the role of contact tracing (June 18) • the role of public health data in controlling the spread of COVID-19 (July 28) • testing for the pathogen (August 18) • recommendations for the coming COVID-19 commission (September 21) • needs for improved epidemiological modeling (September 28) Each report was distributed, upon completion, to selected members of the Trump COVID-19 team and the Biden campaign staff, selected governors and members of Congress, selected public health experts outside government, and the media. The reports have also been posted on the OPCAST team’s website, http://opcast.org, together with a few opinion pieces based on them. In the current volume, we have assembled all six reports in full, preceded by a set of brief summaries. Four of the reports are followed by short updates taking account of developments since the reports first came out.
    [Show full text]
  • Masks Off: Officials Reevaluating Mandates for Indoor Mask Use by Leandra Bernstein Monday, May 10Th 2021
    Masks off: Officials reevaluating mandates for indoor mask use by Leandra Bernstein Monday, May 10th 2021 WASHINGTON (Sinclair Broadcast Group) — Leading public health figures suggested over the weekend that it was time to reevaluate requirements for wearing masks indoors as COVID-19 cases continue to decline and more than half of all American adults have received at least one dose of a vaccine. On CBS's "Face the Nation" Sunday, former commissioner of the Food and Drug Administration Dr. Scott Gottlieb, encouraged jurisdictions with low rates of infection to begin relaxing mask mandates. "I think we're at the point in time when we can start lifting these ordinances in a wholesale fashion," he said, noting that half the states in the country are seeing daily infections at just 10 per 100,000 and almost a quarter have infection rates of 5 in 100,000. The former FDA chief advocated lifting restrictions on outdoor gatherings entirely and eliminating other required mitigation measures under certain criteria. "The states where prevalence is low, vaccination rates are high, and we have good testing in place—we're identifying infections—I think we could start lifting these restrictions indoors as well, on a broad basis," he said. It's possible that mask ordinances may have to be reimplemented if there are outbreaks or if there is a decline in immunity, Gottlieb advised. "But that's a long ways off. We'll worry about that in the fall and the winter," he said. "We're at the point right now where we could start lifting these ordinances and allowing people to resume normal activity." Asked about Dr.
    [Show full text]
  • Developing and Scaling COVID-19 Vaccines May 13, 2020 at 12:30 – 2:30 Pm ET a Webinar by the Duke-Margolis Center for Health Policy and the Alexandria Summit
    Developing and Scaling COVID-19 Vaccines May 13, 2020 at 12:30 – 2:30 pm ET A webinar by the Duke-Margolis Center for Health Policy and the Alexandria Summit Objective: To explore issues, strategies, and policies for developing and scaling COVID-19 vaccines. 12:30 pm Welcome and Overview Mark McClellan, Duke-Margolis Center for Health Policy 12:45 pm Fireside Chat Mark McClellan, Duke-Margolis Center for Health Policy Anthony Fauci, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U.S. Department of Health and Human Services 1:00 pm Envisioning a Path Forward Remarks from Scott Gottlieb, American Enterprise Institute and former Food and Drug Administration, U.S. Department of Health and Human Services 1:05 pm Session One: Vaccine Development This session will explore vaccine development under an accelerated timeline, including strategies to develop or modify technologies, participate in cross-sector collaborations, conduct clinical trials, and achieve approval – all during an active pandemic. Peter Marks, Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services Tal Zaks, Moderna Therapeutics Adrian Hill, Jenner Institute and Oxford Martin Programme on Vaccines John Reed, Sanofi 1:45 pm Session Two: Vaccine Production and Access at Scale This session will explore the scope and scale of manufacturing needs, once a vaccine has been developed and approved, to prepare for demand and ensure appropriate access. Luciana Borio, In-Q-Tel and former National Security Council Director, Medical and Biodefense Preparedness Paul Stoffels, Johnson & Johnson Richard J. Hatchett, Coalition for Epidemic Preparedness Innovation Victor Dzau, National Academy of Medicine 2:25 pm Closing Remarks Joel Marcus, Alexandria Summit; Alexandria Real Estate Equities, Inc./Alexandria Venture Investments Lynne Zydowsky, Alexandria Summit; Alexandria Real Estate Equities, Inc./Alexandria Venture Investments Mark McClellan, Duke-Margolis Center for Health Policy 2:30 pm Adjourn .
    [Show full text]
  • COVID-19 Public Policy Group Report April 25, 2020
    COVID-19 Public Policy Group Report April 25, 2020 President Donald Trump on Friday signed the US$484 Tax and Economic Development Updates billion Paycheck Protection Program and Health Care Enhancement Act into law, triggering a joint announcement With the interim PPP funding bill now signed into law, the by the U.S. Department of the Treasury and Small Business SBA and Treasury Department have indicated that applications Administration (SBA) that the CARES Act‘s Paycheck will be accepted again beginning at 10:30am on Monday, April Protection Program (PPP) will resume operations Monday 27. In a joint statement, Treasury Secretary Mnuchin and SBA morning at 10:30am EST. Meanwhile, details continued to Administrator Jovita Carranza noted: “The PPP has supported trickle out about the respective agendas of the White House more than 1.66 million small businesses and protected and Democratic congressional leadership for negotiations over 30 million jobs for hardworking Americans…With the over the next federal COVID-19 response measure. additional funds appropriated by Congress, tens of millions of additional workers will benefit from this critical relief.” The House Speaker Nancy Pelosi (D-CA) and her lieutenants will two also made clear that the SBA “has properly coded the have the pen in writing the first iteration of the next pandemic system to account for changes,” including the US$60 billion response bill, which House Majority Leader Steny Hoyer (D- set aside for smaller financial institutions. Additionally, the MD) has indicated will be unveiled by May 4. SBA yesterday published additional PPP guidance regarding Congressional Democrats are reportedly eyeing the inclusion requirements for promissory notes, authorizations, affiliation, of another round of direct “stimulus” cash payments to and eligibility.
    [Show full text]
  • The Spreading Cancer of Counterfeit Drugs
    The Spreading Cancer of Counterfeit Drugs The Spreading Cancer of Counterfeit Drugs Pharmaceutical Fakery Metastasizes from Lifestyle to Lifesaving Medicines Pharmaceutical Fakery Metastasizes from LifestyleBy: to Peter Lifesaving J. Pitts Medicines Former FDA Associate Commissioner President, Center By:for MedicinePeter J. Pitts in the Public Interest Former FDA Associate Commissioner President, Center for JulyMedicine 2020 in the Public Interest OctoberJuly 2020 2020 Introduction Just as the coronavirus mutates to survive and thrive, so to do the purveyors of counterfeit medicines – with their high-speed “host” being the digitization of patient care. The future is now. So, how do we balance moving forward with user-friendly digitization, telemedicine and virtual healthcare delivery while simultaneously recognizing the unintended consequences of the innovative criminal mind? The first step is to recognize there’s a problem. Counterfeit Medicines: A Moveable Feast Once upon a time, at the beginning of the new millennium, counterfeit medicines in the United States were largely “lifestyle” products such as erectile dysfunction drugs – Viagra being the poster child of the problem.i Other categories of fake pills included treatments for depression.ii The common denominator was patient shame and embarrassment. Ordering from seemingly benign (i.e., “from Canada”) websites seemed like a safe and anonymous way to address their conditions without having to visit either a physician, mental health professional or pharmacist. A second category of counterfeit prey were people seeking higher risk drugs (opioids, steroids, etc.) to facilitate a more dangerous lifestyle. The rationale for this second group was easier access to more dangerous (often controlled) substances.iii To respond to this emerging threat, the FDA formed a Counterfeit Drug Task Force in July 2003.iv As a former FDA Associate Commissioner, I was proud to serve as a member of that task force.
    [Show full text]
  • Download Open Letter
    1 Supply projections include vaccines produced by Pfizer/BioNTech, Moderna, AstraZeneca/Oxford, Johnson & Johnson, Novavax, and CureVac. Amanda Glassman J. Stephen Morrison Gary Edson Mark McClellan Executive Vice President, Senior Vice President and President, COVID Director, Duke-Margolis Center for Global Director, Global Health Collaborative Center for Health Policy, Development; CEO of CGD Policy Center, Center for Duke University Europe; and Senior Fellow Strategic and International John Bridgeland Studies CEO, COVID Krishna Udayakumar Rachel Silverman Collaborative Director, Duke Global Policy Fellow, Center for Katherine Bliss Health Innovation Center, Global Development Senior Fellow, Global Anjali Balakrishna Duke University Health Policy Center, Program Director, COVID Prashant Yadav Center for Strategic and Collaborative Michael Merson International Studies Senior Fellow, Center for Wolfgang Joklik Professor Global Development of Global Health, Duke Anna McCaffrey Global Health Institute, Fellow, Global Health Duke University Policy Center, Center for Strategic and International Studies Thomas Bollyky Helene Gayle William H. Frist Senior Fellow, Council on Foreign President and Chief Executive Former U.S. Senate Majority Relations Officer, The Chicago Community Leader Trust Scott Gottlieb Margaret (Peggy) Hamburg Amb [ret] Jimmy Kolker Resident Fellow, American Former Commissioner of the US Former Assistant Secretary, Enterprise Institute, and former Food and Drug Administration, Global Affairs, Department Health Commissioner
    [Show full text]
  • Participant Bios
    Sentinel Initiative Public Workshop Participant Biographies Mark McClellan, MD, PhD is director of the Engelberg Center for Health Care Reform and Leonard D. Schaeffer Chair in Health Policy Studies at the Brookings Institution. At the Center, his work focuses on promoting high-quality, innovative and affordable health care. A doctor and economist by training, he also has a highly distinguished record in public service and in academic research. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. These include the Medicare prescription drug benefit, the FDA’s Critical Path Initiative, and public-private initiatives to develop better information on the quality and cost of care. Dr. McClellan chairs the FDA’s Reagan-Udall Foundation, is co-chair of the Quality Alliance Steering Committee, sits on the National Quality Forum’s Board of Directors, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. He previously served as a member of the President’s Council of Economic Advisers and senior director for health care policy at the White House, and was an associate professor of economics and medicine at Stanford University. Margaret Hamburg, MD is Commissioner of Food and Drugs, confirmed on May 18, 2009, by a unanimous Senate vote. The second woman to be nominated for the position, Dr. Hamburg is exceptionally qualified to serve with her training and experience as a medical doctor, scientist, and public health executive.
    [Show full text]
  • Overruling the Food and Drug Administration
    Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Alisha Crovetto, Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action (May 2012). Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10985168 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA Overruling the Food and Drug Administration: An Analysis of the 2011 Denial of Over-the-Counter Status for Plan B Placed within the Historical Context of Executive Influence on FDA Action Alisha Crovetto Harvard Law School J.D. Candidate, 2013 May 2012 Food & Drug Law Course Paper Abstract On December 7, 2011, newspaper headlines from coast to coast announced that Plan B One-Step, a form of emergency contraception, would not be made available to females under seventeen without a prescription. The denial of over-the-counter (“OTC”) status, though newsworthy itself, drew particular attention because of the unusual nature of the decision. As the New York Times announced, “[f]or the first time ever, the Health and Human Services secretary publicly overruled the Food and Drug Administration .
    [Show full text]
  • Aspectos Multidisciplinares Que Envolvem Direito, Gestão E Finanças Acerca Da Covid-19
    Coordenadores Alessandro Aveni Gustavo Javier Castro Silva Jonas Rodrigo Gonçalves ASPECTOS MULTIDISCIPLINARES QUE ENVOLVEM DIREITO, GESTÃO E FINANÇAS ACERCA DA COVID-19 1ª edição 2020 Editora Processus Alessandro Aveni, Gustavo Javier Castro Silva e Jonas Rodrigo Gonçalves. Aspectos multidisciplinares que envolvem Direito, gestão e finanças acerca da Covid-19. Coordenadores Alessandro Aveni, Gustavo Javier Castro Silva e Jonas Rodrigo Gonçalves. Diagramador e capista Danilo da Costa. Editor Jonas Rodrigo Gonçalves. Brasília: Editora Processus, 2020. 1ª edição 357 fls. ISBN: 978-65-88715-00-0 1.Covid-19. 2.Direito. 3.Gestão. 4.Finanças. I.Título. CDU 610 EQUIPE EDITORIAL Diretora Geral Prof. Claudine Fernandes de Araújo Diretor Acadêmico Prof. Dr. Gustavo Javier de Castro Silva, Faculdade Processus-DF, Brasil. Editor-CheFe Prof. MSc. Jonas Rodrigo Gonçalves, Faculdade Processus-DF, Brasil. Conselho editorial Prof. Dr. Aloísio Rucheinki, Universidade do Vale do Rio dos Sinos, Brasil. Prof. Dr. Arnaldo Santos Bastos, Universidade Federal de Goiás, Brasil. Profa. Dra. Caroline de Abreu Batista Claro, Universidade de Brasília, Brasil. Profa. Dra. Estefânia Naiara da Silva Lino, Universidade de Rio Verde, Brasil. Prof. Dr. Gustavo Rabay Guerra, Universidade, Federal da Paraíba, Brasil. Prof. Dr. Henrique Smidt Simon, Universidade Euro-Americano, Brasil. Prof. Dr. José Eduardo Souza de Miranda, Universidade de Cantabria, Santander, Espanha. Prof. Dr. Márcio Petrocelli Paixão, Universidade Federal do Rio de Janeiro, Brasil Profa. Msc. Patrícia Spagnollo Parise, Universidade de Rio Verde, Brasil Prof. Dr. Rildo Mourão Ferreira, Universidade de Rio Verde Avaliadores Prof. Dr. Arthur Henrique de Pontes Regis, Universidade de Brasília, Brasil. Prof. Dr. Gustavo Javier Castro Silva, Faculdade Processus-DF, Brasil.
    [Show full text]
  • After a COVID-19 Vaccine: Collaboration Or Competition?
    Entry Point nations like the US move to lock up fu- ture supplies of experimental COVID-19 vaccines through individual deals with manufacturers even as other countries pool their resources to develop and eq- uitably distribute vaccines through the World Health Organization (WHO)– sponsored COVID-19 Vaccine Global Ac- cess Facility (COVAX).1,2 Experts discussed these unprecedent- ed opportunities and challenges at a Health Affairs online symposium, “Pro- moting Innovation and Equity as COVID- 19 Vaccines and Treatment Emerge,” presented August 24, 2020. There was excitement among the speakers about the rapid, pandemic- driven advances in science, clinical trial, and regulatory processes and collabora- tions among governments, manufac- turers, and nongovernmental organiza- tions that could improve global health in the future. But there were deep concerns about whether the US, China, and other countries will be able to transcend na- tionalist rivalries to defeat their com- Vaccine: Volunteer Melissa Harting, from Harpersville, New York, receives a COVID-19 vaccine mon viral foe and whether profit incen- injection from nurse Kathe Olmstead. Harting is participating in the world’s largest study of a possible COVID-19 vaccine, developed by the National Institutes of Health and Moderna Inc. tives will get in the way. “We can choose to collaborate and bring the world back to health equitably, doi: 10.1377/hlthaff.2020.01732 or we can compete and exacerbate in- equities,” Orin Levine, director of Glob- al Delivery Programs at the Bill & After A COVID-19 Vaccine: Melinda Gates Foundation, said in his opening remarks. “A moment is coming soon when we have a breakthrough on a Collaboration Or lifesaving vaccine.
    [Show full text]
  • Reducing Global COVID Vaccine Shortages
    Reducing Global COVID Vaccine Shortages: New Research and Recommendations for US Leadership April 15, 2021 Mark McClellan, MD, PhD Krishna Udayakumar, MD, MBA Michael Merson, MD Gary Edson, JD, MBA Authors Mark McClellan, Duke-Margolis Center for Michael Merson, Duke Global Health Health Policy Institute Krishna Udayakumar, Duke Global Health Gary Edson, COVID Collaborative Innovation Center Acknowledgements We thank Beth Boyer and Adam Kroetsch for assistance with our analyses and editing, and Morgan Romine and Patricia Green for editing and design support. We also thank Mark Dybul and Steve Morrison for helpful feedback on various aspects of this report. Disclosures Mark McClellan, MD, PhD, directs the Duke-Margolis Center for Health Policy, was Commissioner of the Food and Drug Administration from 2002-04 and Administrator of the Centers for Medicare and Medicaid Services from 2004-06. He is an independent director on the boards of Johnson & Johnson, Cigna, Alignment Healthcare, and PrognomIQ; co-chairs the Guiding Committee for the Health Care Payment Learning and Action Network; and receives fees for serving as an advisor for Arsenal Capital Partners, Blackstone Life Sciences, and MITRE. Krishna Udayakumar, MD, MBA, reports that the following organizations have provided research and operational support (funding and/or in-kind) through Duke-affiliated non-profit, Innovations in Healthcare, and/or Duke University in the past 12 months, or direct fees/honoraria, or represent equity holdings: Amazon, Amgen, AstraZeneca, Bayer, Bill and Melinda Gates Foundation, Grand Challenges Canada, McKinsey & Company, Medtronic, Pfizer, Pfizer Foundation, Takeda, USAID, Vynamic, WeberShandwick, World Economic Forum. Michael H Merson, MD, reports in the past 12 months fees/honoraria for serving as an advisor to Weber Shandwick and the National Basketball Association.
    [Show full text]
  • The Petrie Flom Center for Health Law Policy, Biotechnology, and Bioethics Annual Report of Activities 2010-2011
    The Petrie Flom Center for Health Law Policy, Biotechnology, and Bioethics Annual Report of Activities 2010-2011 Executive Summary 2010-2011 has been another successful year for the Center, as we further advanced our position as the preeminent academic institution examining how law intersects with health care, bioethics, and biotechnology. That success was, however, tinged with sadness by the news of Joe Flom’s passing. The Center is the realization of the vision that Joe and the Petrie Foundation set out for the Law School, and we remain grateful for his foresight and generosity. We are proud to carry forward the mantle of his name. Our academic fellowship program, offering two years of support and mentorship for post- graduates, continues its remarkable record as a pipeline to top academic positions in health law. After turning down several other offers, our outgoing fellows ultimately accepted professor appointments at the law schools at Cornell and the University of Illinois, adding to the Center’s prior placements at Harvard, UC Berkeley, UCLA, Boston University, and the University of Arizona. Our current academic fellows are working on papers in topics such as rethinking conflicts of interest policies in academic medicine and reforming human subjects protection, and we are excited to welcome in two additional fellows beginning this summer. Our fellows and faculty published or have forthcoming award-winning work not only in the leading law reviews, but also in medicine (The New England Journal of Medicine), science (Nature, Cell), economics (The American Economic Review), and bioethics (The American Journal of Bioethics, The Hastings Center Report).
    [Show full text]